HOME >> BIOLOGY >> NEWS
New bipolar survey: Patients' satisfaction influenced

Vienna, June 29th 2005 Preliminary results from a large-scale global study of people living with bipolar disorder,1 presented today at the World Congress of Biological Psychiatry (WCBP), found that patient satisfaction with treatment is achieved through combining broad-based efficacy with a favourable tolerability profile.

The Thinking Ahead Survey,1 included 687 bipolar patients from seven countries (UK, US, Germany, Italy, Canada, Spain and Greece). These preliminary results indicate that:

  • 88% of respondents said drug treatment satisfaction is largely influenced by how effective it is, followed then by patients experiencing few or manageable side effects (77%)

  • 79% of respondents believe that a successful treatment would be one which leads to significant quality of life changes in terms of increased functionality and improved lifestyle

Bipolar disorder, also known as manic-depressive illness, is a severe biological disorder that affects approximately 3-4% of the adult population.5,6 More than half of those with bipolar disorder stop taking their medication at some point during their illness, subjecting themselves to a high risk of relapse and an increased risk of suicide.7

"As someone who lives with bipolar disorder I need a treatment which can control the manic symptoms but also treat the more disabling depressive symptoms," comments Michael Grinter, SEROQUEL patient and Thinking Ahead Taskforce member. "The treatment that I am currently taking, SEROQUEL, has brought an enormous benefit to my life in terms of controlling both poles of my mood and has enabled me to return to work and live a fully functioning life. It has provided me with the confidence to enjoy each day again."

Recently-published SEROQUEL (quetiapine) data in the Journal of Current Medical Research and Opinion confirm SEROQUEL's efficacy and tolerability in the treatment of bipolar mania symp
'"/>

Contact: Lisa O'Sullivan
lisa.o'sullivan@shirehealthinternational.com
44-207-108-6515
Shire Health International
29-Jun-2005


Page: 1 2 3

Related biology news :

1. New databases put wings on search for bipolar risk genes
2. $9M grant awarded to University of Cincinnati for bipolar disorder research
3. Genetic roots of bipolar disorder revealed by first genome-wide study of illness
4. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
5. Gene controlling circadian rhythms may be involved in onset of bipolar disorder
6. Extreme irritability -- is it childhood bipolar disorder?
7. Fear circuit flares as bipolar youth misread faces
8. Clock molecules sensitivity to lithium sheds light on bipolar disorder
9. Link suggested between regions on two chromosomes and bipolar disorder
10. Research zeros in on bipolar disorder genes, link with thyroid condition
11. Beyond lithium for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
Breaking Biology Technology:
Cached News: